Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

ByBenjamin P. Levy, MD,Parth Rao, MD,Daniel J. Becker, MD,Kevin Becker, MD

July 16th 2016

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Latest Updated Articles

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
July 16th 2016

Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Latest Updated Articles

Trending on CancerNetwork

From Conference to Practice: Top 5 Takeaways From EHA 2026

58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative

57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers

ASCO 2026: Key Insights In Renal Cell Carcinoma, Merkel Cell Carcinoma, and Chronic Myeloid Leukemia

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma